Skip to main content
Mark Jacobson, MD, Infectious Disease, San Francisco, CA, Zuckerberg San Francisco General Hospital and Trauma Center

MarkAndrewJacobsonMD

Infectious Disease • San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Jacobson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jacobson's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1984 - 1986
  • Kaiser Permanente Northern California (Oakland)
    Kaiser Permanente Northern California (Oakland)Residency, Internal Medicine, 1981 - 1984
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1982 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • HIV Epitope Specific T Cell Responses And Control Of HIV ReplicationNational Institute Of Allergy And Infectious Diseases2007–2008
  • Aberrant T Cell Function And Immunopathogenesis Of CMV Immune Recovery UveitisNational Eye Institute2007–2008
  • The Role Of Protein Loop Flexibility In Substrate BindingNational Center For Research Resources2006
  • The Role Of Protein Loop Flexibility In Substrate BindingNational Center For Research Resources2005
  • CMV Immune Response &Long-Term Outcome Of CMV RetinitisNational Eye Institute2004–2005
  • Adjuvant Rhil-12 With A CytomegalovirusNational Center For Research Resources2004–2005
  • Aactg 5079: Physiologic TestosteroneNational Center For Research Resources2004–2005
  • ACTG 5077: Haart/Hiv CompartmentsNational Center For Research Resources2004
  • Aactg A5082: Metformin/ RosiglitazoneNational Center For Research Resources2004
  • A5159: HIV Protease Inhibitors And Calcium Channel BlockersNational Center For Research Resources2004
  • Adjunct Rhil-12 Enhance Thi Response To Viral Vaccine?National Institute Of Allergy And Infectious Diseases2002–2004
  • Salvage Antiretroviral Therapy For HIV+ PatientsNational Center For Research Resources2000–2002
  • Quadruple Drug Treatment With 3tc/Zdv PLUS ABC PLUS APV In HIV InfectionNational Center For Research Resources2000–2002
  • PI And NRTI In HIV TherapyNational Center For Research Resources2000–2002
  • Phase I Trial Of IL-12 In HIV Infected SubjectsNational Center For Research Resources2000–2002
  • Interaction Between PI And Lipid Lowering AgentsNational Center For Research Resources2000–2002
  • HIV Protease Inhibitors And Methadone Metabolism In HIV+ SubjectsNational Center For Research Resources2000–2002
  • Dmp-266 Or Nfv PLUS Combivir And Indinavir In HIVNational Center For Research Resources2000–2002
  • Discontinuing Therapy For Disseminated MACNational Center For Research Resources2000–2002
  • Amprenavir As PART Of Dual Protease Inhibitor RegimensNational Center For Research Resources2000–2002
  • Core--ClinicalNational Institute Of Mental Health1998–2001
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–2001
  • ACTG 387: Paired Combinations Of Nelfinavir, Ritonavir, &SaquinavirNational Center For Research Resources1999–2000
  • Safety, Tolerance And Activity On Plasma Viremia Of SCH 52000 In HIVNational Center For Research Resources1998–2000
  • Trial To Evaluate Tolerability, Anti CMV Activity/Pharmacokinetics Of 1263w94National Center For Research Resources1997–2000
  • Fluconazole, Clarithromycin, Rifabutin/Sulfamethoxazole And DapsoneNational Center For Research Resources1997–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--ClinicalNational Institute Of Allergy And Infectious Diseases1994–1998
  • Oral Ganciclovir After Treatment With IV Ganciclovir For CMV GI DiseaseNational Center For Research Resources1996–1997
  • Hpmpc Peripheral CMV Retinitis TrialNational Center For Research Resources1996–1997
  • Recombinant Human Interleukin 12 In HIV Infected Subjects--301 To 500 CD4 CellsNational Center For Research Resources1996
  • Recombinant Human Interleukin 12 In HIV Infected Subjects--100 To 300 CD4 CellsNational Center For Research Resources1996
  • Recombinant Human Interleukin 12 In HIV Infected Subjects (301-500 CD4 Cells)National Center For Research Resources1995
  • Recombinant Human Interleukin 12 In HIV Infected Subjects (100-300 CD4 Cells)National Center For Research Resources1995
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995

Hospital Affiliations

Dr. Mark Jacobson, Dr. Mark Jacobson, MD, Dr. M Jacobson, Dr. Mark Andrew Jacobson